Literature DB >> 20974571

SEOM clinical guidelines for the treatment of antiemetic prophylaxis in cancer patients receiving chemotherapy.

Jesús García Gómez1, M Eva Pérez López, Jesús García Mata, Dolores Isla Casado.   

Abstract

Chemotherapy-induced emesis is one of the most frequent side effects that affect the quality of life of cancer patients undergoing chemotherapy. In recent years, clinical research has allowed us to increase our therapeutic arsenal with new drugs that have increased efficiency in the control of nausea and vomiting associated with chemo. This guide provides and update of the earlier published by our society and represents the continued commitment of SEOM to move forward and improve in the supportive care of cancer patients.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20974571     DOI： 10.1007/s12094-010-0594-5

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN： 1699-048X            Impact factor:   3.405


  24 in total

Review 1.  Comparative review of 5-HT3 receptor antagonists in the treatment of acute chemotherapy-induced nausea and vomiting.

Authors:  P J Hesketh
Journal:  Cancer Invest       Date:  2000       Impact factor: 2.176

Review 2.  Antiemetic therapy for multiple-day chemotherapy and high-dose chemotherapy with stem cell transplant: review and consensus statement.

Authors:  Lawrence H Einhorn; Bernardo Rapoport; Jim Koeller; Steven M Grunberg; Petra Feyer; Cynthia Rittenberg; Matti Aapro
Journal:  Support Care Cancer       Date:  2004-10-09       Impact factor: 3.603

Review 3.  Clinical practice guidelines on antiemetics in oncology.

Authors:  Enrique Aranda Aguilar; Manuel Constenla Figueiras; Hernán Cortes-Funes; Eduardo Diaz-Rubio García; Pere Gascon Vilaplana; Vicente Guillém; Salvador Martin-Algarra
Journal:  Expert Rev Anticancer Ther       Date:  2005-12       Impact factor: 4.512

4.  Chemotherapy-induced nausea and vomiting: ESMO clinical recommendations for prophylaxis.

Authors:  J Herrstedt; F Roila
Journal:  Ann Oncol       Date:  2008-05       Impact factor: 32.976

Review 5.  Anticipatory nausea and vomiting.

Authors:  Matti S Aapro; Alexander Molassiotis; Ian Olver
Journal:  Support Care Cancer       Date:  2004-12-15       Impact factor: 3.603

6.  American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006.

Authors:  Mark G Kris; Paul J Hesketh; Mark R Somerfield; Petra Feyer; Rebecca Clark-Snow; James M Koeller; Gary R Morrow; Lawrence W Chinnery; Maurice J Chesney; Richard J Gralla; Steven M Grunberg
Journal:  J Clin Oncol       Date:  2006-05-22       Impact factor: 44.544

Review 7.  Pathogenesis-based treatment of chemotherapy-induced nausea and vomiting--two new agents.

Authors:  Rudolph M Navari
Journal:  J Support Oncol       Date:  2003 Jul-Aug

Review 8.  Control of chemotherapy-induced emesis.

Authors:  S M Grunberg; P J Hesketh
Journal:  N Engl J Med       Date:  1993-12-09       Impact factor: 91.245

9.  Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron.

Authors:  R Gralla; M Lichinitser; S Van Der Vegt; H Sleeboom; J Mezger; C Peschel; G Tonini; R Labianca; A Macciocchi; M Aapro
Journal:  Ann Oncol       Date:  2003-10       Impact factor: 32.976

10.  Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron.

Authors:  Peter Eisenberg; Jazmin Figueroa-Vadillo; Rosalio Zamora; Veena Charu; Julio Hajdenberg; Alan Cartmell; Alberto Macciocchi; Steven Grunberg
Journal:  Cancer       Date:  2003-12-01       Impact factor: 6.860
View more
  5 in total

Review 1.  Chemotherapy-induced nausea and vomiting: pathophysiology and therapeutic principles.

Authors:  Juan Bayo; Paula J Fonseca; Susana Hernando; S Servitja; A Calvo; S Falagan; Estefanía García; Iria González; María José de Miguel; Quionia Pérez; Ana Milena; Antonio Ruiz; Agustí Barnadas
Journal:  Clin Transl Oncol       Date:  2012-06       Impact factor: 3.405

2.  The relevance of the Spanish Society for Medical Oncology (SEOM)'s clinical oncology guidelines.

Authors:  Dolores Isla Casado; Antonio González-Martín; Emilio Alba Conejo
Journal:  Clin Transl Oncol       Date:  2010-11       Impact factor: 3.405

3.  SEOM Clinical Guideline update for the prevention of chemotherapy-induced nausea and vomiting (2016).

Authors:  R de Las Peñas; A Blasco; J De Castro; Y Escobar; R García-Campelo; A Gúrpide; R Lopez-Lopez; M Majem; C A Rodríguez; J A Virizuela
Journal:  Clin Transl Oncol       Date:  2016-11-28       Impact factor: 3.405

Review 4.  NEPA, a new fixed combination of netupitant and palonosetron, is a cost-effective intervention for the prevention of chemotherapy-induced nausea and vomiting in the UK.

Authors:  Helene Cawston; Francois Bourhis; Jennifer Eriksson; Pierfrancesco Ruffo; Paolo D'Agostino; Marco Turini; Lee Schwartzberg; Alistair McGuire
Journal:  Drugs Context       Date:  2017-03-24

5.  Randomized pharmacokinetic study comparing subcutaneous and intravenous palonosetron in cancer patients treated with platinum based chemotherapy.

Authors:  Belen Sadaba; Anabel del Barrio; Miguel Angel Campanero; Jose Ramon Azanza; Almudena Gomez-Guiu; Jose Maria Lopez-Picazo; Salvador Martin Algarra; Francisco Guillén Grimá; Maria Blanco Prieto; Jose Luis Perez-Gracia; Alfonso Gurpide
Journal:  PLoS One       Date:  2014-02-27       Impact factor: 3.240
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.